Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A humorous look at the companies that caught our eye, for better or worse, this week

L Brands (STAR)

In a world gone mad, sometimes you just have to light some eucalyptus mint candles and pour yourself a lavender vanilla bubble bath. Shareholders of L Brands enjoyed the soothing experience of watching their shares rise after the company said sales at Bath & Body Works – which sells these and other fine products – are expected to soar 10 per cent in the second quarter, even as many of its stores were temporarily shut because of the pandemic. With L Brands also announcing US$400-million of cost cuts and 250 store closings at struggling Victoria’s Secret – which L Brands plans to split off as a separate company – investors are suddenly feeling much more relaxed.

LB - NYSE

Story continues below advertisement

Stuart Olson (DOG)

Normally, when a company receives a takeover offer, its shares rise. Unfortunately for shareholders of Stuart Olson, its battered stock headed even lower. Bird Construction announced the acquisition of the Calgary-based construction services company for $96.5-million in cash and shares. But given what Stuart Olson’s CEO called the company’s “balance sheet and leverage metrics challenges,” almost all of the money will go to Stuart Olson’s lenders, with just $4-million ending up in the pockets of shareholders. So much for a takeover premium.

SOX - TSX

Procter & Gamble (STAR)

Upside of staying home during the coronavirus pandemic: More time to clean your house, do your laundry and practise good dental hygiene. Shares of Procter & Gamble – whose brands include Tide laundry detergent, Mr. Clean household cleaners and Crest toothpaste – jumped after the consumer products giant posted net sales growth of 4 per cent to US$17.7-billion for the three months to June 30, as earnings of US$2.8-billion or US$1.07 a share topped expectations. Investors are cleaning up.

PG - NYSE

Eastman Kodak (STAR)

Two things you may not know about Eastman Kodak: 1) The company still exists; 2) It’s about to get into the drug business. Shares of the company – which filed for bankruptcy protection in 2012 and largely got out of consumer photography to focus on corporate digital imaging – soared after the Trump administration awarded Kodak a US$765-million loan to start producing generic pharmaceutical ingredients under the Defense Production Act. Why pick a failed camera company to do the job instead of a generic drug maker? Good question. “We are puzzled by the Trump administration’s decision,” SVB Leerink analysts said in a note.

KODK - NYSE

Cameco (DOG)

You say Cam-ee-co, I say Cam-e-co, let’s call the whole thing off. Some Cameco investors were calling it quits after the uranium producer posted a bigger-than-expected quarterly loss of $53-million, including $37-million in costs tied to the shutdown of operations and increased reliance on spot uranium purchases during the coronavirus pandemic. Cameco said it has “the tools we need to deal with the current uncertain environment,” including $878-million in cash and short-term assets and a $1-billion untapped credit facility. But with the stock struggling for years, some investors are evidently getting impatient.

Story continues below advertisement

CCO - TSX

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies